In this episode of This Week in Intelligent Investing, hosts John Mihaljevic and Elliot Turner welcome Peter Mantas, General Partner and Chief Investment Officer at Logos LP. Recorded on May 12, 2026, the discussion dives deep into the rapidly shifting landscape of biotechnology and life sciences investing.

Peter breaks down the recent regulatory drama at the FDA, the profound impact of artificial intelligence on drug discovery, and the economic realities of life-changing gene therapies. With a unique interdisciplinary background spanning corporate law and capital markets, Peter offers a masterclass on finding asymmetric, uncorrelated value in a highly complex sector.

Key Topics Discussed:

FDA Shakeups & Regulatory Shifts: The resignation of Marty Makary and what the removal of the "MAHA movement" influence means for the future of gene and cell therapy approvals.
The uniQure Saga: A deep dive into uniQure's AMT-130 for Huntington's disease, the ethical implications of requiring Phase 3 trials for devastating rare diseases, and the growing regulatory pressure on the US from the UK and EU.
Biotech Infrastructure & "Picks and Shovels": How regulatory bottlenecks and delayed approvals compress valuations for life sciences tools and drug delivery companies like ClearPoint Neuro and Repligen.
AI as a Biotech "Coiled Spring": Why AI is drastically cutting the cost of knowledge in preclinical discovery, and why regulatory frameworks must adapt to prevent a massive clinical bottleneck.
Pricing Curative Therapies: The math behind why health insurers are willing to pay millions for single-dose gene therapies that cure patients and restore them to the active workforce.
Building an Edge: How Peter transitioned into a specialized biotech investor, how he uses AI as a "pocket analyst," and insights from his Substack publication, Back of the Napkin Bios.

The primary purpose of this podcast is to educate and inform. The views, information, or opinions expressed by hosts or guests are their own. Neither this show, nor any of its content should be construed as investment advice or as a recommendation to buy or sell any particular security. Security specific information shared on this podcast should not be relied upon as a basis for your own investment decisions -- be sure to do your own research. The podcast hosts and participants may have a position in the securities mentioned, personally, through sub accounts and/or through separate funds and may change their holdings at any time.

About the Guest:

Peter Mantas is the General Partner and Chief Investment Officer at Logos LP, a privately held investment firm specializing in interdisciplinary value investing. With a robust background spanning finance, law, and technology, Peter brings a multifaceted perspective to capital markets and business advisory. Alongside his work at Logos LP, he is the Co-Founder and Co-Managing Partner at Orion Legal Group. Earlier in his career, Peter served as a corporate lawyer in the capital markets and alternative investments groups at McCarthy Tétrault LLP and held management positions within international technology firms, including Wolters Kluwer and Proofpoint. A frequent speaker and commentator on emerging technologies, life sciences, and portfolio construction, Peter is also known for his work on the Back of the Napkin Bios podcast series. He holds an Honours Baccalaureate in Commerce from the University of Ottawa and both an LL.B. and B.C.L. from McGill University’s Faculty of Law.

About the Co-Hosts:

Elliot Turner is a co-founder and Managing Partner, CIO at RGA Investment Advisors, LLC. RGA Investment Advisors runs a long-term, low turnover, growth at a reasonable price investment strategy seeking out global opportunities. Elliot focuses on discovering and analyzing long-term, high quality investment opportunities and strategic portfolio management. Prior to joining RGA, Elliot managed portfolios at at AustinWeston Asset Management LLC, Chimera Securities and T3 Capital. Elliot holds the Chartered Financial Analyst (CFA) designation as well as a Juris Doctor from Brooklyn Law School.. He also holds a Bachelor of Arts degree from Emory University where he double majored in Political Science and Philosophy.

John Mihaljevic leads MOI Global and serves as managing editor of The Manual of Ideas. He managed a private partnership, Mihaljevic Partners LP, from 2005-2016. John is a winner of the Value Investors Club’s prize for best investment idea. He is a trained capital allocator, having studied under Yale University Chief Investment Officer David Swensen and served as Research Assistant to Nobel Laureate James Tobin. John holds a BA in Economics, summa cum laude, from Yale and is a CFA charterholder.